{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T10:01:34Z","timestamp":1787652094907,"version":"build-2736575974"},"update-to":[{"DOI":"10.1002\/14651858.cd007654.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,3,2]],"date-time":"2016-03-02T00:00:00Z","timestamp":1456876800000}}],"reference-count":196,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd007654.pub4","type":"journal-article","created":{"date-parts":[[2016,3,5]],"date-time":"2016-03-05T14:07:34Z","timestamp":1457186854000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Long-term effects of weight-reducing drugs in people with hypertension"],"prefix":"10.1002","author":[{"given":"Andrea","family":"Siebenhofer","sequence":"first","affiliation":[{"name":"Graz, Austria \/ Institute of General Practice, Goethe University; Institute of General Practice and Evidence-Based Health Services Research, Medical University of Graz; Frankfurt am Main Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Jeitler","sequence":"additional","affiliation":[{"name":"Medical University of Graz; Institute of General Practice and Evidence-Based Health Services Research \/ Institute of Medical Informatics, Statistics and Documentation; Auenbruggerplatz 2\/9 Graz Austria 8036"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Horvath","sequence":"additional","affiliation":[{"name":"Medical University of Graz; Institute of General Practice and Evidence-Based Health Services Research \/ Department of Internal Medicine, Division of Endocrinology and Metabolism; Auenbruggerplatz 2\/9 Graz Austria 8036"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Berghold","sequence":"additional","affiliation":[{"name":"Medical University of Graz; Institute of General Practice and Evidence-Based Health Services Research \/ Institute of Medical Informatics, Statistics and Documentation; Auenbruggerplatz 2\/9 Graz Austria 8036"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Posch","sequence":"additional","affiliation":[{"name":"Medical University of Graz; Institute of General Practice and Evidence-Based Health Services Research; Auenbruggerplatz 2\/9 Graz Austria 8036"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutta","family":"Meschik","sequence":"additional","affiliation":[{"name":"Medical University of Graz; Institute of General Practice and Evidence-Based Health Services Research; Auenbruggerplatz 2\/9 Graz Austria 8036"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Semlitsch","sequence":"additional","affiliation":[{"name":"Medical University of Graz; Institute of General Practice and Evidence-Based Health Services Research; Auenbruggerplatz 2\/9 Graz Austria 8036"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,3,2]]},"reference":[{"issue":"11","key":"10.1002\/14651858.CD007654.pub4-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1097\/00004872-200211000-00026","article-title":"Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension","volume":"20","author":"Bakris","year":"2002","journal-title":"Journal of Hypertension"},{"issue":"2","key":"10.1002\/14651858.CD007654.pub4-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1159\/000083662","article-title":"Sufficient weight reduction decreases cardiovascular complications in diabetic patients with the metabolic syndrome: A randomized study of orlistat as an adjunct to lifestyle changes (diet and exercise)","volume":"5","author":"Cocco","year":"2005","journal-title":"Heart Drug"},{"issue":"Suppl1","key":"10.1002\/14651858.CD007654.pub4-BIB0003|cit3","first-page":"S284","article-title":"Weight loss and improvements in cardiometabolic outcomes with extended-release phentermine\/topiramate treatment in overweight\/obese subjects with type 2 diabetes","volume":"55","author":"Astrup","year":"2012","journal-title":"Diabetologia"},{"issue":"Suppl1","key":"10.1002\/14651858.CD007654.pub4-BIB0004|cit4","first-page":"S168","article-title":"Reduction of cardiovascular risk factors by magnitude of weight loss in obese and overweight subjects with >2 comorbidities","volume":"28","author":"Cheskin","year":"2013","journal-title":"Journal of General Internal Medicine"},{"issue":"Suppl1","key":"10.1002\/14651858.CD007654.pub4-BIB0005|cit5","first-page":"A710","article-title":"Improved cardiometabolic risk factors in overweight\/obese subjects receiving controlled-release phentermine\/topiramate (PHEN\/TPM CR)","volume":"61","author":"Cheskin","year":"2012","journal-title":"Diabetes"},{"issue":"14, Supplement","key":"10.1002\/14651858.CD007654.pub4-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"E545","DOI":"10.1016\/S0735-1097(11)60545-7","article-title":"Weight loss and cardiovascular risk reduction over 2 years with controlled-release phentermine-topiramate","volume":"57","author":"Davidson","year":"2011","journal-title":"Journal of the American College of Cardiology"},{"issue":"8","key":"10.1002\/14651858.CD007654.pub4-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.amjcard.2012.12.038","article-title":"Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index >27 kg\/m(2)","volume":"111","author":"Davidson","year":"2013","journal-title":"American Journal of Cardiology"},{"issue":"Suppl1","key":"10.1002\/14651858.CD007654.pub4-BIB0008|cit8","first-page":"45","article-title":"Weight loss and improvements in blood pressure (BP) status associated with phentermine and topiramate extended-release (PHEN\/TPM ER) treatment in obese and overweight adults","volume":"6","author":"Finer","year":"2013","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0009|cit9","first-page":"(var. pagings)","article-title":"Magnitude of weight loss experienced with a low-dose, controlled-release formulation of phentermine\/topiramate (PHEN\/TPM) may drive degree of cardiometabolic benefit","volume":"Conference Publ","author":"Gadde","year":"2010","journal-title":"Diabetes"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD007654.pub4-BIB0010|cit10","first-page":"S2","article-title":"12-month weight loss and antihypertensive benefits with PHEN\/TPM in overweight and obese subjects with hypertension","volume":"17","author":"Gadde","year":"2010","journal-title":"European Journal of Cardiovascular Prevention and Rehabilitation"},{"issue":"9774","key":"10.1002\/14651858.CD007654.pub4-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","article-title":"Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.[Erratum appears in Lancet. 2011 Apr 30;377(9776):1494]","volume":"377","author":"Gadde","year":"2011","journal-title":"The Lancet"},{"issue":"Suppl1","key":"10.1002\/14651858.CD007654.pub4-BIB0012|cit12","first-page":"42","article-title":"Low-dose, controlled-release phentermine\/topiramate for reduction of weight, related risks in overweight\/obese adults with >2 comorbidities","volume":"11","author":"Gadde","year":"2010","journal-title":"Obesity Reviews"},{"issue":"1 Supplement","key":"10.1002\/14651858.CD007654.pub4-BIB0013|cit13","first-page":"S308","article-title":"Once-daily, low-dose, controlled-release phentermine\/topiramate results in significant clinical improvements in overweight\/obese patients with type 2 diabetes","volume":"53","author":"Garvey","year":"2010","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0014|cit14","first-page":"(var. pagings)","article-title":"Changes in insulin sensitivity in overweight\/obese patients treated with low-dose, controlled-release phentermine\/topiramate (PHEN\/TPM)","volume":"Conference Publ","author":"Garvey","year":"2010","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0015|cit15","first-page":"(var. pagings)","article-title":"Improvements in dyslipidemia and other cardiometabolic disease risk factors with low-dose, controlled-release phentermine\/topiramate (PHEN\/TPM)","volume":"Conference Publ","author":"Garvey","year":"2010","journal-title":"Diabetes"},{"issue":"Suppl1","key":"10.1002\/14651858.CD007654.pub4-BIB0016|cit16","first-page":"A506","article-title":"Weight loss with controlled-release phentermine\/topiramate (PHEN\/TPM CR) reverses metabolic syndrome (MetS) and improves associated traits","volume":"60","author":"Garvey","year":"2011","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"(12 Meeting Abs","DOI":"10.1161\/circ.127.suppl_12.AP027","article-title":"Obesity treatment-induced weight loss improves resting blood pressure and reduces progression from prehypertension to hypertension in overweight\/obese adults","volume":"127","author":"Gupta","year":"2013","journal-title":"Circulation"},{"issue":"Suppl1","key":"10.1002\/14651858.CD007654.pub4-BIB0018|cit18","first-page":"S241","article-title":"Weight loss with phentermine and topiramate extended-release in obese and overweight subjects over 56 weeks","volume":"28","author":"Kushner","year":"2013","journal-title":"Journal of General Internal Medicine"},{"issue":"Suppl1","key":"10.1002\/14651858.CD007654.pub4-BIB0019|cit19","first-page":"S285","article-title":"Effects of extended-release phentermine\/topiramate on weight loss and blood pressure in obese subjects with type 2 diabetes mellitus","volume":"55","author":"Rossner","year":"2012","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0020|cit20","first-page":"(3 Meeting Abst","article-title":"Achievement of composite of recommended goals in obese subjects with type 2 diabetes mellitus using extended-release phentermine\/topiramate in a 56-week weight loss intervention","volume":"33","author":"Ryan","year":"2012","journal-title":"Endocrine Reviews"},{"issue":"Suppl1","key":"10.1002\/14651858.CD007654.pub4-BIB0021|cit21","first-page":"S39","article-title":"Low-dose controlled-release phentermine\/topiramate (PHEN\/TPM CR) results in significant weight loss and improves atherosclerotic biomarkers in overweight\/obese patients with obesity-related comorbidities","volume":"89","author":"Troupin","year":"2011","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD007654.pub4-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF02850257","article-title":"Safety and efficacy of sibutramine in overweight Hispanic patients with hypertension","volume":"20","author":"Fangh\u00e4nel","year":"2003","journal-title":"Advances in Therapy"},{"issue":"3","key":"10.1002\/14651858.CD007654.pub4-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1463-1326.2005.00465.x","article-title":"Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients","volume":"7","author":"Faria","year":"2005","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD007654.pub4-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1590\/S0066-782X2002000200006","article-title":"Effects of sibutramine on the treatment of obesity in patients with arterial hypertension. [Portuguese, English]","volume":"78","author":"Faria","year":"2002","journal-title":"Arquivos Brasileiros de Cardiologia"},{"issue":"5","key":"10.1002\/14651858.CD007654.pub4-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1462-8902.2004.00359.x","article-title":"Effects of orlistat on obesity-related diseases - a six-month randomized trial","volume":"6","author":"Guy-Grand","year":"2004","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"14","key":"10.1002\/14651858.CD007654.pub4-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1001\/archinte.160.14.2185","article-title":"Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial","volume":"160","author":"McMahon","year":"2000","journal-title":"Archives of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD007654.pub4-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/sj.jhh.1001298","article-title":"Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors","volume":"16","author":"McMahon","year":"2002","journal-title":"Journal of Human Hypertension"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0028|cit28","first-page":"19","article-title":"Evaluation of the benefits and harms of non-drug weight-reducing treatment strategies in patients with essential hypertension","volume-title":"http:\/\/iqwig.de\/download\/A05-21A_Abschlussbericht_Gewichtsreduktion_bei_Bluthochdruck_neu.pdf","author":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen","year":"2006"},{"issue":"5","key":"10.1002\/14651858.CD007654.pub4-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0197-2456(01)00165-9","article-title":"Principles for enhanced recruitment of subjects in a large clinical trial. the XENDOS (XENical in the prevention of Diabetes in Obese Subjects) study experience","volume":"22","author":"Torgerson","year":"2001","journal-title":"Controlled Clinical Trials"},{"issue":"1","key":"10.1002\/14651858.CD007654.pub4-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/diacare.27.1.155","article-title":"XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients","volume":"27","author":"Torgerson","year":"2004","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1002\/14651858.CD007654.pub4-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0002-9343(98)00411-2","article-title":"Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine","volume":"106","author":"Apfelbaum","year":"1999","journal-title":"American Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD007654.pub4-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/j.1550-8528.1999.tb00419.x","article-title":"Absence of cardiac valve dysfunction in obese patients treated with sibutramine","volume":"7","author":"Bach","year":"1999","journal-title":"Obesity Research"},{"issue":"Suppl1","key":"10.1002\/14651858.CD007654.pub4-BIB0033|cit33","first-page":"71","article-title":"A randomised, placebo-controlled trial of liraglutide as adjunct to basal insulin analogues in subjects with Type 2 diabetes (LIRA-ADD2BASAL)","volume":"32","author":"Bain","year":"2015","journal-title":"Diabetic Medicine"},{"issue":"3","key":"10.1002\/14651858.CD007654.pub4-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJMoa0909809","article-title":"Multicenter, placebo-controlled trial of lorcaserin for weight management","volume":"363","author":"Smith","year":"2010","journal-title":"The New England Journal of Medicine"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0035|cit35","first-page":"LB24","article-title":"Lorcaserin reduces body weight in obese and overweight subjects: Behavioral modification and lorcaserin for overweight and obesity management, the BLOOM trial","volume":"58","author":"Smith","year":"2009","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0036|cit36","unstructured":"Fidler MC Shazer R Sanchez M Stubbe S Anderson CM Shanahan WR Lorcaserin, a selective 5-HT2C agonist, evaluated as a weight loss agent in obese and overweight patients with type 2 diabetes treated with sulfonylureas or metformin Diabetes 2011 A515"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0037|cit37","doi-asserted-by":"crossref","unstructured":"O'Neil PM Fidler MC Sanchez M Weissman NJ Smith SR Anderson CM Randomized, placebo-controlled trial of lorcaserin for weight loss in patients with type 2 diabetes Diabetes 2011 A507","DOI":"10.1038\/oby.2012.66"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0038|cit38","doi-asserted-by":"crossref","unstructured":"O'Neil PM Smith SR Weissman NJ Fidler MC Sanchez M Zhang J Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study Obesity 2012 1426 36","DOI":"10.1038\/oby.2012.66"},{"issue":"2","key":"10.1002\/14651858.CD007654.pub4-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/j.1550-8528.1999.tb00701.x","article-title":"Sibutramine produces dose-related weight loss","volume":"7","author":"Bray","year":"1999","journal-title":"Obesity Research"},{"issue":"7","key":"10.1002\/14651858.CD007654.pub4-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1742-1241.2002.tb11307.x","article-title":"Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study","volume":"56","author":"Broom","year":"2002","journal-title":"International Journal of Clinical Practice"},{"issue":"Suppl1","key":"10.1002\/14651858.CD007654.pub4-BIB0041|cit41","first-page":"S179","article-title":"Naltrexone SR\/bupropion SR and intensive behavioral modification combination increases the likelihood of achieving early and sustained weight loss and associated improvement in markers of cardiometabolic risk","volume":"19","author":"O'Neil","year":"2011","journal-title":"Obesity"},{"issue":"1","key":"10.1002\/14651858.CD007654.pub4-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/oby.2010.147","article-title":"Weight loss with naltrexone SR\/bupropion SR combination therapy as an adjunct to behavior modification: The COR-BMOD trial","volume":"19","author":"Wadden","year":"2011","journal-title":"Obesity"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.2337\/dc13-0234","article-title":"Effects of naltrexone sustained-release\/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes","volume":"36","author":"Hollander","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0044|cit44","first-page":"A520","article-title":"Weight loss and improvements in markers of metabolic risk in overweight and obese subjects completing 56 weeks of treatment with naltrexone SR\/bupropion SR","volume":"60","author":"Fujioka","year":"2011","journal-title":"Diabetes"},{"issue":"Suppl1","key":"10.1002\/14651858.CD007654.pub4-BIB0045|cit45","first-page":"S179","article-title":"Completion of 56 weeks of naltrexone SR\/bupropion SR combination therapy increases likelihood of achieving improvements in markers of cardiometabolic risk associated with clinically meaningful weight loss","volume":"19","author":"Fujioka","year":"2011","journal-title":"Obesity"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","article-title":"Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"376","author":"Greenway","year":"2010","journal-title":"The Lancet"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0047|cit47","first-page":"A700","article-title":"Response to NB at week 16 is a good predictor of significant week 56 weight loss and improvements in weight-related risk factors","volume":"60","author":"Plutzky","year":"2011","journal-title":"Diabetes"},{"issue":"5","key":"10.1002\/14651858.CD007654.pub4-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/oby.20309","article-title":"A randomized, phase 3 trial of naltrexone SR\/bupropion SR on weight and obesity-related risk factors (COR-II)","volume":"21","author":"Apovian","year":"2013","journal-title":"Obesity"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0049|cit49","first-page":"A506","article-title":"Naltrexone SR\/bupropion SR combination therapy improves control of eating and reduces food cravings in overweight and obese subjects","volume":"60","author":"Hill","year":"2011","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0050|cit50","first-page":"A506","article-title":"Naltrexone SR\/bupropion SR combination therapy reduced weight and improved weight-related quality of life and physical health in overweight and obese subjects","volume":"60","author":"Kolotkin","year":"2011","journal-title":"Diabetes"},{"issue":"14, Supplement","key":"10.1002\/14651858.CD007654.pub4-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"E517","DOI":"10.1016\/S0735-1097(11)60517-2","article-title":"Weight loss, blood pressure, pulse and circadian patterns with naltrexone sustained-release\/bupropion sustained-release combination therapy for obesity","volume":"57","author":"Plutzky","year":"2011","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0052|cit52","first-page":"A504","article-title":"Effects of naltrexone SR\/bupropion SR on weight and obesity-related health risks in overweight\/obese women from the COR-II trial","volume":"60","author":"Rubino","year":"2011","journal-title":"Diabetes"},{"issue":"3","key":"10.1002\/14651858.CD007654.pub4-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jama.281.3.235","article-title":"Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial [see comment] [erratum appears in JAMA 1999 Apr 7;281(13):1174]","volume":"281","author":"Davidson","year":"1999","journal-title":"JAMA"},{"issue":"12","key":"10.1002\/14651858.CD007654.pub4-BIB0054|cit54","first-page":"1361","article-title":"A randomized double-blind study comparing the efficacy and safety of orlistat versus placebo in obese patients with mild to moderate hypercholesterolemia","volume":"28","author":"Castro","year":"2009","journal-title":"Revista Portuguesa de Cardiologia"},{"issue":"4","key":"10.1002\/14651858.CD007654.pub4-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0149-2918(03)80070-X","article-title":"Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet","volume":"25","author":"Derosa","year":"2003","journal-title":"Clinical Therapeutics"},{"issue":"11","key":"10.1002\/14651858.CD007654.pub4-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.metabol.2008.06.010","article-title":"Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone","volume":"57","author":"Derosa","year":"2008","journal-title":"Metabolism: Clinical & Experimental"},{"issue":"3","key":"10.1002\/14651858.CD007654.pub4-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"378","DOI":"10.18433\/J3388P","article-title":"Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients","volume":"13","author":"Derosa","year":"2010","journal-title":"Journal of Pharmacy and Pharmaceutical Sciences"},{"issue":"5","key":"10.1002\/14651858.CD007654.pub4-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1365-2710.2010.01217.x","article-title":"Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients","volume":"36","author":"Derosa","year":"2011","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"issue":"20","key":"10.1002\/14651858.CD007654.pub4-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa044537","article-title":"Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia","volume":"353","author":"Despres","year":"2005","journal-title":"The New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD007654.pub4-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1161\/ATVBAHA.108.176362","article-title":"Effect of rimonabant on the high-triglyceride\/low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial","volume":"29","author":"Despres","year":"2009","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"3","key":"10.1002\/14651858.CD007654.pub4-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1067\/mhj.2001.117510","article-title":"Effects of sibutramine on body weight and serum lipids: A double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia","volume":"142","author":"Dujovne","year":"2001","journal-title":"American Heart Journal"},{"issue":"2","key":"10.1002\/14651858.CD007654.pub4-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/oby.2011.330","article-title":"Controlled-release phentermine\/topiramate in severely obese adults: a randomized controlled trial (EQUIP)","volume":"20","author":"Allison","year":"2012","journal-title":"Obesity"},{"issue":"11","key":"10.1002\/14651858.CD007654.pub4-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/j.1365-2036.2004.01966.x","article-title":"Cholesterol lowering effect of dietary weight loss and orlistat treatment - Efficacy and limitations","volume":"19","author":"Erdmann","year":"2004","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD007654.pub4-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/sj.ijo.0801098","article-title":"A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity","volume":"24","author":"Fangh\u00e4nel","year":"2000","journal-title":"International Journal of Obesity & Related Metabolic Disorders: Journal of the International Association for the Study of Obesity"},{"issue":"5","key":"10.1002\/14651858.CD007654.pub4-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/sj.ijo.0801592","article-title":"Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over","volume":"25","author":"Fangh\u00e4nel","year":"2001","journal-title":"International Journal of Obesity & Related Metabolic Disorders: Journal of the International Association for the Study of Obesity"},{"issue":"3","key":"10.1002\/14651858.CD007654.pub4-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/sj.ijo.0801128","article-title":"One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor","volume":"24","author":"Finer","year":"2000","journal-title":"International Journal of Obesity & Related Metabolic Disorders: Journal of the International Association for the Study of Obesity"},{"issue":"3","key":"10.1002\/14651858.CD007654.pub4-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1046\/j.1463-1326.2000.00081.x","article-title":"Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus","volume":"2","author":"Fujioka","year":"2000","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"S1","key":"10.1002\/14651858.CD007654.pub4-BIB0068|cit68","first-page":"S77","article-title":"Treatment with VI-0521 (phentermine and topiramate) leads to one year durable glycaemic benefit and weight loss in subjects with type 2 diabetes","volume":"52","author":"Garvey","year":"2009","journal-title":"Diabetologia"},{"issue":"Suppl. 1","key":"10.1002\/14651858.CD007654.pub4-BIB0069|cit69","first-page":"A95","article-title":"One-year treatment with VI-0521 in type 2 diabetes demonstrates continued glycemic improvement and weight loss","volume":"58","author":"Garvey","year":"2009","journal-title":"Diabetes"},{"issue":"2","key":"10.1002\/14651858.CD007654.pub4-BIB0070|cit70","first-page":"90","article-title":"Efficacy and safety of a short-time orlistat treatment in obese subjects. [Italian]","volume":"20","author":"Gentile","year":"2005","journal-title":"Annali Italiani di Medicina Interna"},{"issue":"7","key":"10.1002\/14651858.CD007654.pub4-BIB0071|cit71","first-page":"24","article-title":"Add-on sibutramine for olanzapine-induced weight gain","volume":"11","author":"Ginsberg","year":"2004","journal-title":"Primary Psychiatry"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1210\/jc.2009-1350","article-title":"Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo","volume":"94","author":"Greenway","year":"2009","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"3","key":"10.1002\/14651858.CD007654.pub4-BIB0073|cit73","first-page":"98","article-title":"Evaluation of efficacy, reliability, and tolerability of sibutramine in obese patients, with an echocardiographic study","volume":"57","author":"Halpern","year":"2002","journal-title":"Revista do Hospital das Clinicas; Faculdade de Medicina Da Universidade de Sao Paulo"},{"issue":"3","key":"10.1002\/14651858.CD007654.pub4-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1046\/j.1463-1326.2003.00262.x","article-title":"Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients","volume":"5","author":"Halpern","year":"2003","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"4","key":"10.1002\/14651858.CD007654.pub4-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1055\/s-2004-817934","article-title":"Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study","volume":"112","author":"Hauner","year":"2004","journal-title":"Experimental & Clinical Endocrinology & Diabetes"},{"issue":"2","key":"10.1002\/14651858.CD007654.pub4-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1001\/archfami.9.2.160","article-title":"Orlistat in the long-term treatment of obesity in primary care settings","volume":"9","author":"Hauptman","year":"2000","journal-title":"Archives of Family Medicine"},{"issue":"9","key":"10.1002\/14651858.CD007654.pub4-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.numecd.2008.12.008","article-title":"Effect of diet-induced weight loss on plasma apelin and cytokine levels in individuals with the metabolic syndrome","volume":"19","author":"Heinonen","year":"2009","journal-title":"Nutrition, Metabolism and Cardiovascular Diseases"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD007654.pub4-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.amjmed.2006.11.014","article-title":"Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus","volume":"120","author":"Hollander","year":"2007","journal-title":"American Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD007654.pub4-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/j.1464-5491.2005.01569.x","article-title":"Sibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with Type 2 diabetes","volume":"22","author":"Hung","year":"2005","journal-title":"Diabetic Medicine"},{"issue":"2","key":"10.1002\/14651858.CD007654.pub4-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"99","DOI":"10.4103\/2230-8210.81938","article-title":"Evaluation of efficacy and safety of orlistat in obese patients","volume":"15","author":"Jain","year":"2011","journal-title":"Indian Journal of Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0081|cit81","first-page":"S24","article-title":"A one-year trial to assess the value of orlistat in the management of obesity","volume":"21 Suppl 3","author":"James","year":"1997","journal-title":"International Journal of Obesity & Related Metabolic Disorders: Journal of the International Association for the Study of Obesity"},{"issue":"9248","key":"10.1002\/14651858.CD007654.pub4-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0140-6736(00)03491-7","article-title":"Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance [see comment]","volume":"356","author":"James","year":"2000","journal-title":"The Lancet"},{"issue":"25","key":"10.1002\/14651858.CD007654.pub4-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1056\/NEJMc1009975","article-title":"Trial of lorcaserin for weight management","volume":"363","author":"Jia","year":"2010","journal-title":"The New England Journal of Medicine"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0084|cit84","first-page":"S285","article-title":"Effects of phentermine and extended-release topiramate alone and in combination on cardiovascular risk factors","volume":"55","author":"Jordan","year":"2012","journal-title":"Diabetologia"},{"issue":"4","key":"10.1002\/14651858.CD007654.pub4-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/sj.ijo.0802591","article-title":"Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes","volume":"28","author":"Kaukua","year":"2004","journal-title":"International Journal of Obesity & Related Metabolic Disorders: Journal of the International Association for the Study of Obesity"},{"issue":"6","key":"10.1002\/14651858.CD007654.pub4-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2337\/diacare.25.6.1033","article-title":"Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial [erratum appears in Diabetes Care 2003 Mar;26(3):971]","volume":"25","author":"Kelley","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0087|cit87","first-page":"393","article-title":"Weight loss achieved with medication can delay onset of type 2 diabetes in at-risk individuals","volume":"21","author":"Lewis","year":"2014","journal-title":"Journal of Clinical Outcomes Management"},{"issue":"3","key":"10.1002\/14651858.CD007654.pub4-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1365-2796.2000.00720.x","article-title":"The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study [see comment]","volume":"248","author":"Lindgarde","year":"2000","journal-title":"Journal of Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD007654.pub4-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1136\/ebm.6.2.54","article-title":"Orlistat with diet was effective and safe for weight loss and coronary risk reduction in obesity","volume":"6","author":"Lindgarde","year":"2001","journal-title":"Evidence-Based Medicine"},{"issue":"1","key":"10.1002\/14651858.CD007654.pub4-BIB0090|cit90","first-page":"171","article-title":"Effect of orlistat on coronary heart disease risk in obese patients with hypertension and\/or hyperlipidemia","volume":"141","author":"Lindgarde","year":"2001","journal-title":"American Heart Journal"},{"issue":"7","key":"10.1002\/14651858.CD007654.pub4-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.metabol.2009.02.031","article-title":"Long-term weight loss decreases the nontraditional cardiovascular risk factors interleukin-18 and matrix metalloproteinase-9 in obese subjects","volume":"58","author":"Madsen","year":"2009","journal-title":"Metabolism"},{"issue":"1","key":"10.1002\/14651858.CD007654.pub4-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2337\/diacare.26.1.125","article-title":"A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin","volume":"26","author":"McNulty","year":"2003","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1002\/14651858.CD007654.pub4-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.2337\/diacare.25.7.1123","article-title":"Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin [erratum appears in Diabetes Care 2002 Sep;25(9):1671]","volume":"25","author":"Miles","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0094|cit94","first-page":"S56","article-title":"Liraglutide once daily reduces the prevalence of prediabetes and metabolic syndrome in obese non-diabetic adults: A 2-year randomized trial","volume":"18","author":"Niskanen","year":"2010","journal-title":"Obesity"},{"issue":"13","key":"10.1002\/14651858.CD007654.pub4-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1001\/jama.299.13.1547","article-title":"Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial","volume":"299","author":"Nissen","year":"2008","journal-title":"JAMA"},{"issue":"14","key":"10.1002\/14651858.CD007654.pub4-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/hrt.2011.223446","article-title":"Effect of rimonabant on carotid intima-media thickness (CIMT) progression in patients with abdominal obesity and metabolic syndrome: the AUDITOR Trial","volume":"97","author":"O'Leary","year":"2011","journal-title":"Heart"},{"issue":"1","key":"10.1002\/14651858.CD007654.pub4-BIB0097|cit97","first-page":"1","article-title":"Orlistat as an adjunct therapy in type 2 obese diabetic patients treated with sulphonylurea: a Bangladesh experience","volume":"30","author":"Pathan","year":"2004","journal-title":"Bangladesh Medical Research Council Bulletin"},{"issue":"12","key":"10.1002\/14651858.CD007654.pub4-BIB0098|cit98","first-page":"32","article-title":"Obesity-related hypertension","volume":"24","author":"Patschan","year":"2007","journal-title":"Cardiology Review"},{"issue":"7","key":"10.1002\/14651858.CD007654.pub4-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.295.7.761","article-title":"Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial [see comment] [erratum appears in JAMA 2006 Mar 15;295(11):1252]","volume":"295","author":"Pi-Sunyer","year":"2006","journal-title":"JAMA"},{"issue":"7","key":"10.1002\/14651858.CD007654.pub4-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0002-9149(00)01521-6","article-title":"Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X","volume":"87","author":"Reaven","year":"2001","journal-title":"American Journal of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD007654.pub4-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/oby.2000.8","article-title":"Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group","volume":"8","author":"Rossner","year":"2000","journal-title":"Obesity Research"},{"issue":"15","key":"10.1002\/14651858.CD007654.pub4-BIB0102|cit102","first-page":"1802","article-title":"Sibutramine - antidepressive agent tested against obesity. [Swedish]","volume":"98","author":"Rossner","year":"2001","journal-title":"Lakartidningen"},{"issue":"3","key":"10.1002\/14651858.CD007654.pub4-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1046\/j.1463-1326.2003.00264.x","article-title":"Decreasing levels of tumour necrosis factor alpha and interleukin 6 during lowering of body mass index with orlistat or placebo in obese subjects with cardiovascular risk factors","volume":"5","author":"Samuelsson","year":"2003","journal-title":"Diabetes, Obesity and Metabolism"},{"issue":"Suppl1","key":"10.1002\/14651858.CD007654.pub4-BIB0104|cit104","first-page":"S83","article-title":"Effect of liraglutide 3.0\/1.8 mg on body weight and cardiometabolic risk factors in overweight\/obese adults with type 2 diabetes: SCALE diabetes randomised, double-blind, 56-week trial","volume":"57","author":"Bode","year":"2014","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0105|cit105","first-page":"72","article-title":"Liraglutide 3.0mg results in significant weight loss and improvements in cardiometabolic risk factors compared with liraglutide 1.8mg or placebo: A randomised, double-blind, 56 week trial in overweight\/obese adults with Type 2 diabetes (SCALE diabetes)","volume":"32","author":"Davies","year":"2015","journal-title":"Diabetic Medicine"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0106|cit106","first-page":"124","article-title":"Diet-induced weight loss and subsequent addition of liraglutide 3.0 mg reduces impaired fasting glucose in overweight\/obese adults in the scaleTM maintenance 56-week randomised trial","volume":"5","author":"Hollander","year":"2013","journal-title":"Journal of Diabetes"},{"issue":"Suppl1","key":"10.1002\/14651858.CD007654.pub4-BIB0107|cit107","first-page":"S368","article-title":"Efficacy and safety of liraglutide 3.0 mg for weight management in overweight\/obese adults: The SCALE obesity and prediabetes trial","volume":"57","author":"Fujioka","year":"2014","journal-title":"Diabetologia"},{"issue":"Suppl1","key":"10.1002\/14651858.CD007654.pub4-BIB0108|cit108","first-page":"S368","article-title":"Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight\/obese adults: The SCALE obesity and prediabetes randomised trial","volume":"57","author":"Krempf","year":"2014","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.orcp.2014.10.210","article-title":"Efficacy and safety of liraglutide 3.0mg for weight management in overweight and obese adults: The SCALE obesity and prediabetes, a randomised, double-blind and placebo-controlled trial","volume":"8","author":"Proietto","year":"2014","journal-title":"Obesity Research and Clinical Practice"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0110|cit110","first-page":"15","article-title":"Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: The scaleTM obesity and prediabetes, a randomised, double-blind and placebo-controlled trial","volume":"7","author":"Wilding","year":"2014","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0111|cit111","first-page":"70","article-title":"Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre-diabetes trial","volume":"32","author":"Wilding","year":"2015","journal-title":"Diabetic Medicine"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.orcp.2014.10.211","article-title":"Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: The SCALE Obesity and Prediabetes randomised, double-blind, placebo-controlled 56-week trial","volume":"8","author":"Wittert","year":"2014","journal-title":"Obesity Research and Clinical Practice"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"A16","DOI":"10.1136\/thoraxjnl-2014-206260.34","article-title":"Liraglutide 3.0 mg reduces severity of obstructive sleep apnoea and body weight in obese individuals with moderate or severe disease: Scale sleep apnoea trial","volume":"69","author":"Collier","year":"2014","journal-title":"Thorax"},{"issue":"6 I","key":"10.1002\/14651858.CD007654.pub4-BIB0114|cit114","first-page":"437","article-title":"New antiobesity agents in type 2 diabetes: Overview of clinical trials with sibutramine and orlistat","volume":"28","author":"Scheen","year":"2002","journal-title":"Diabetes and Metabolism"},{"issue":"var.pagings). 5","key":"10.1002\/14651858.CD007654.pub4-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"A141.E1326","DOI":"10.1016\/S0735-1097(10)61327-7","article-title":"Effects on mortality and morbidity in overweight\/obese subjects: The sibutramine cardiovascular outcomes (SCOUT) trial","volume":"Conference: Ame","author":"James","year":"2010","journal-title":"Journal of the American College of Cardiology"},{"issue":"10","key":"10.1002\/14651858.CD007654.pub4-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMoa1003114","article-title":"Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects","volume":"363","author":"James","year":"2010","journal-title":"The New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD007654.pub4-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/FJC.0b013e31818713d6","article-title":"Tolerability of sibutramine during a 6-week treatment period in high-risk patients with cardiovascular disease and\/or diabetes: a preliminary analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial","volume":"52","author":"Maggioni","year":"2008","journal-title":"Journal of Cardiovascular Pharmacology"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0118|cit118","first-page":"173","article-title":"Changes in body weight and blood pressure: Paradoxical outcome events in overweight and obese subjects with cardiovascular disease","volume":"15","author":"Seimon","year":"2014","journal-title":"Obesity Reviews"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/ijo.2014.2","article-title":"Changes in body weight and blood pressure: paradoxical outcome events in overweight and obese subjects with cardiovascular disease","volume":"38","author":"Seimon","year":"2014","journal-title":"International Journal of Obesity"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0120|cit120","first-page":"S176","article-title":"Significant weight loss with controlled-release phentermine\/topiramate (PHEN\/TPM CR) is associated with significant reductions in use of concomitant medications for cardiometabolic diseases over 108 weeks","volume":"19","author":"Garvey","year":"2011","journal-title":"Obesity"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"912","DOI":"10.2337\/dc13-1518","article-title":"Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release","volume":"37","author":"Garvey","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3945\/ajcn.111.024927","article-title":"Two-year sustained weight loss and metabolic benefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL): A randomized, placebo-controlled, phase 3 extension study","volume":"95","author":"Garvey","year":"2012","journal-title":"American Journal of Clinical Nutrition"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0123|cit123","first-page":"S177","article-title":"Weight loss (WL) with low-dose, controlled-release phentermine\/topiramate (PHEN\/TPM CR) correlates with improvements in liver function in overweight\/obese adults with elevated alanine aminotransferase (ALT)","volume":"19","author":"Klein","year":"2011","journal-title":"Obesity"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0124|cit124","first-page":"S370","article-title":"Long-term weight loss with controlled-release phentermine\/topiramate reverses metabolic syndrome and improves associated traits","volume":"54","author":"Toplak","year":"2011","journal-title":"Diabetologia"},{"issue":"9123","key":"10.1002\/14651858.CD007654.pub4-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0140-6736(97)11509-4","article-title":"Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group [see comment]","volume":"352","author":"Sjostrom","year":"1998","journal-title":"The Lancet"},{"issue":"4","key":"10.1002\/14651858.CD007654.pub4-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/oby.2001.29","article-title":"Influence of sibutramine on energy expenditure in African American women","volume":"9","author":"Starling","year":"2001","journal-title":"Obesity Research"},{"issue":"1","key":"10.1002\/14651858.CD007654.pub4-BIB0127|cit127","first-page":"179","article-title":"Comparison of efficacy and safety of rimonabant with orlistat in obese and overweight patients","volume":"2","author":"Suyog","year":"2011","journal-title":"International Journal of Pharma and Bio Sciences"},{"issue":"2","key":"10.1002\/14651858.CD007654.pub4-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/oby.2007.82","article-title":"Effect of orlistat on eating behavior among participants in a 3-year weight maintenance trial","volume":"16","author":"Svendsen","year":"2008","journal-title":"Obesity (Silver Spring)"},{"issue":"3","key":"10.1002\/14651858.CD007654.pub4-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1463-1326.2004.00467.x","article-title":"Effect of orlistat on cardiovascular disease risk in obese adults","volume":"7","author":"Swinburn","year":"2005","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"5","key":"10.1002\/14651858.CD007654.pub4-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1046\/j.1463-1326.2003.00285.x","article-title":"Sibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double-blind, randomized, placebo-controlled trial","volume":"5","author":"Tambascia","year":"2003","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"1","key":"10.1002\/14651858.CD007654.pub4-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/ajcn\/79.1.22","article-title":"Effects of equal weight loss with orlistat and placebo on body fat and serum fatty acid composition and insulin resistance in obese women","volume":"79","author":"Tiikkainen","year":"2004","journal-title":"American Journal of Clinical Nutrition"},{"issue":"3","key":"10.1002\/14651858.CD007654.pub4-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1210\/jc.2011-2486","article-title":"Does rimonabant independently affect free fatty acid and glucose metabolism?","volume":"97","author":"Triay","year":"2012","journal-title":"JCEM"},{"issue":"8","key":"10.1002\/14651858.CD007654.pub4-BIB0133|cit133","first-page":"E248","article-title":"Cardioprotective effects of antihypertensive therapy with orlistat treatment and hypocaloric diet in combination in obese hypertensive patients","volume":"115","author":"Tunyan","year":"2007","journal-title":"Circulation"},{"issue":"9468","key":"10.1002\/14651858.CD007654.pub4-BIB0134|cit134","first-page":"1389","article-title":"Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study [see comment] [erratum appears in Lancet 2005 Jul 30-Aug 5;366(9483):370]","volume":"365","author":"Gaal","year":"2005","journal-title":"The Lancet"},{"issue":"14","key":"10.1002\/14651858.CD007654.pub4-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1093\/eurheartj\/ehn076","article-title":"Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study","volume":"29","author":"Gaal","year":"2008","journal-title":"European Heart Journal"},{"issue":"11","key":"10.1002\/14651858.CD007654.pub4-BIB0136|cit136","first-page":"651","article-title":"Orlistat for adjuvant treatment of fatty type 2 diabetes mellitus in 32 patients","volume":"22","author":"Wang","year":"2003","journal-title":"Zhongguo xin yao yu lin chuang za zhi [Chinese journal of new drugs and clinical remedies]"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0137|cit137","first-page":"A297","article-title":"The effects of once-daily 15mg phentermine plus 92mg topiramate extended-release (PHEN\/TPM ER) on cardiometabolic endpoints in obese patients with obstructive sleep apnea","volume":"36","author":"Winslow","year":"2013","journal-title":"Sleep"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.5665\/sleep.2204","article-title":"A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine\/topiramate for the treatment of obstructive sleep apnea in obese adults","volume":"35","author":"Winslow","year":"2012","journal-title":"Sleep"},{"issue":"11","key":"10.1002\/14651858.CD007654.pub4-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1001\/jama.286.11.1331","article-title":"Long-term weight loss with sibutramine: a randomized controlled trial","volume":"286","author":"Wirth","year":"2001","journal-title":"JAMA"},{"issue":"3","key":"10.1002\/14651858.CD007654.pub4-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1067\/mhj.2002.124403","article-title":"Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction","volume":"144","author":"Zannad","year":"2002","journal-title":"American Heart Journal"},{"issue":"12 Pt 2","key":"10.1002\/14651858.CD007654.pub4-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1097\/00004872-199816121-00024","article-title":"Treatment with orlistat reduces cardiovascular risk in obese patients","volume":"16","author":"Zavoral","year":"1998","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0142|cit142","first-page":"68","article-title":"Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADERTM) trial: Rationale and study design","volume":"29","author":"Bain","year":"2012","journal-title":"Diabetic Medicine"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0143|cit143","first-page":"A612","article-title":"Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADERTM) trial: Rationale and study design","volume":"60","author":"Bergenstal","year":"2011","journal-title":"Diabetes"},{"issue":"2","key":"10.1002\/14651858.CD007654.pub4-BIB0144|cit144","first-page":"104","article-title":"Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (leader) trial: Rationale and study design","volume":"19","author":"Consoli","year":"2012","journal-title":"High Blood Pressure and Cardiovascular Prevention"},{"issue":"1, Suppl 1","key":"10.1002\/14651858.CD007654.pub4-BIB0145|cit145","first-page":"86","article-title":"Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) Trial: Rationale and study design","volume":"6","author":"Mannucci","year":"2012","journal-title":"Italian Journal of Medicine"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.ahj.2013.07.012","article-title":"Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial","volume":"166","author":"Marso","year":"2013","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0147|cit147","unstructured":"Abbott Germany. Theobald F Press release: [Abbott setzt Vertrieb seiner Medikamente mit dem Wirkstoff Sibutramin zur Behandlung von Adipositas in den L\u00e4ndern der Europ\u00e4ischen Union aus.] 2010 Available from: http:\/\/www.abbott.de\/press\/show\/e7340\/e19695\/e18095\/Sibutramin_210110_Theobald_de.pdf"},{"issue":"2","key":"10.1002\/14651858.CD007654.pub4-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1210\/jc.2014-3415","article-title":"Pharmacological management of obesity: an Endocrine Society clinical practice guideline","volume":"100","author":"Apovian","year":"2015","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"issue":"11","key":"10.1002\/14651858.CD007654.pub4-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/oby.20584","article-title":"Evaluation of phentermine and topiramate versus phentermine\/topiramate extended-release in obese adults","volume":"21","author":"Aronne","year":"2013","journal-title":"Obesity (Silver Spring, Md.)"},{"issue":"6","key":"10.1002\/14651858.CD007654.pub4-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1161\/01.HYP.0000165680.59733.d4","article-title":"Effects of weight loss in overweight\/obese individuals and long-term hypertension outcomes: a systematic review","volume":"45","author":"Aucott","year":"2005","journal-title":"Hypertension"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.2147\/DDDT.S55587","article-title":"Naltrexone sustained-release\/bupropion sustained-release for the management of obesity: review of the data to date","volume":"8","author":"Caixas","year":"2014","journal-title":"Drug Design, Development and Therapy"},{"issue":"5","key":"10.1002\/14651858.CD007654.pub4-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/obr.12015","article-title":"Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs","volume":"14","author":"Chan","year":"2013","journal-title":"Obesity Reviews: an official journal of the International Association for the Study of Obesity"},{"issue":"5","key":"10.1002\/14651858.CD007654.pub4-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.cjca.2014.02.002","article-title":"The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension","volume":"30","author":"Dasgupta","year":"2014","journal-title":"Canadian Journal of Cardiology"},{"issue":"9740","key":"10.1002\/14651858.CD007654.pub4-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(10)60935-X","article-title":"Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial","volume":"376","author":"Topol","year":"2010","journal-title":"The Lancet"},{"issue":"1","key":"10.1002\/14651858.CD007654.pub4-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1463-1326.2004.00372.x","article-title":"Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients","volume":"7","author":"Derosa","year":"2005","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0156|cit156","unstructured":"European Medicines Agency (EMA) Questions and answers on the recommendation to suspend the marketing authorisation of Acomplia (rimonabant) Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Medicine_QA\/2009\/11\/WC500014779.pdf"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0157|cit157","unstructured":"European Medicines Agency (EMA) Press Release - The European Medicines Agency recommends suspension of the marketing authorisation of Acomplia Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Press_release\/2009\/11\/WC500014774.pdf"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0158|cit158","unstructured":"European Medicines Agency (EMA) Public Statement on\u00a0Acomplia (rimonabant) - Withdrawal of the marketing authorisation in the European Union Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Public_statement\/2009\/11\/WC500012189.pdf"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0159|cit159","unstructured":"European Medicines Agency (EMA) Victoza (liraglutide) - EPAR - Summary for the public Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/001026\/WC500050013.pdf"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0160|cit160","unstructured":"European Medicines Agency (EMA) Press Release - European Medicines Agency recommends suspension of marketing authorisations for sibutramine Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Press_release\/2010\/01\/WC500069995.pdf"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0161|cit161","unstructured":"European Medicines Agency (EMA) Questions and answers on the suspension of medicines containing sibutramine Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Sibutramine_107\/WC500094238.pdf"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0162|cit162","unstructured":"European Medicines Agency (EMA) Questions and answers on the withdrawal of the marketing authorisation application for Belviq (lorcaserin) Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Medicine_QA\/2013\/05\/WC500143811.pdf"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0163|cit163","unstructured":"European Medicines Agency (EMA) Withdrawal assessment report for Belviq Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Application_withdrawal_assessment_report\/human\/002597\/WC500148196.pdf"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0164|cit164","unstructured":"European Medicines Agency (EMA) Questions and answers on the refusal of the marketing authorisation for Qsiva (phentermine\/topiramate) Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Summary_of_opinion_-_Initial_authorisation\/human\/002350\/WC500139215.pdf"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0165|cit165","unstructured":"European Medicines Agency (EMA) Scientific conclusions and grounds for refusal of the marketing authorisation for Qsiva (13 June 2013) Available from: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002350\/human_med_001607.jsp&mid=WC0b01ac058001d124#"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0166|cit166","unstructured":"European Medicines Agency (EMA) Mysimba (naltrexone\/bupropion) - EPAR summary for the public Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/003687\/WC500185583.pdf"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0167|cit167","unstructured":"European Medicines Agency (EMA) Saxenda (liraglutide) - EPAR summary for the public Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/003780\/WC500185789.pdf"},{"issue":"1","key":"10.1002\/14651858.CD007654.pub4-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/08037051.2014.868629","article-title":"2013 ESH\/ESC Practice Guidelines for the Management of Arterial Hypertension","volume":"23","author":"Mancia","year":"2014","journal-title":"Blood Pressure"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0169|cit169","unstructured":"US Food Drug Administration. Egan AG Colman EG FDA Rimonabant Briefing Document. Endocrine and Metabolic Drugs Advisory Committee. 2007 Available from: http:\/\/www.fda.gov\/ohrms\/dockets\/AC\/07\/briefing\/2007-4306b1-fda-backgrounder.pdf"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0170|cit170","unstructured":"US Food Drug Administration (FDA) Recommendation on a regulatory decision for Meridia (sibutramine) Available from: http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM228795.pdf"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0171|cit171","unstructured":"US Food Drug Administration (FDA) FDA News Release: Abbott Laboratories agrees to withdraw its obesity drug Meridia Available from: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/2010\/ucm228812.htm"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0172|cit172","unstructured":"US Food Drug Administration (FDA) Victoza (Liraglutide (rDNA)) - Approval letter Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/022341s000approv.pdf"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0173|cit173","unstructured":"US Food Drug Administration (FDA) Qsymia (phentermine and topiramate extended-release) - Approval letter Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/022580Orig1s000Approv.pdf"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0174|cit174","unstructured":"US Food Drug Administration (FDA) Contrave (naltrexone hydrochloride\/bupropion hydrochloride) - Approval letter Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/200063Orig1s000Approv.pdf"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0175|cit175","unstructured":"US Food Drug Administration (FDA) Saxenda (liraglutide) - Approval letter Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2014\/206321Orig1s000ltr.pdf"},{"issue":"10","key":"10.1002\/14651858.CD007654.pub4-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1210\/jc.2011-1256","article-title":"A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial","volume":"96","author":"Fidler","year":"2011","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0177|cit177","unstructured":"Higgins JPT Green S(editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"6","key":"10.1002\/14651858.CD007654.pub4-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1001\/archinte.168.6.571","article-title":"Long-term effects of weight-reducing interventions in hypertensive patients: systematic review and meta-analysis","volume":"168","author":"Horvath","year":"2008","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0179|cit179","first-page":"19","article-title":"Evaluation of the benefits and harms of non-drug weight-reducing treatment strategies in patients with essential hypertension","volume-title":"Available from: http:\/\/iqwig.de\/download\/A05-21A_Abschlussbericht_Gewichtsreduktion_bei_Bluthochdruck_neu.pdf","author":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen","year":"2006"},{"issue":"5","key":"10.1002\/14651858.CD007654.pub4-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"issue":"9","key":"10.1002\/14651858.CD007654.pub4-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/oby.2003.152","article-title":"Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials","volume":"11","author":"Kim","year":"2003","journal-title":"Obesity Research"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0182|cit182","unstructured":"NEJM Journal Watch FDA reminds clinicians of liraglutide\u2019s risks for pancreatitis and cancer Available from: http:\/\/www.jwatch.org\/fw201106140000002\/2011\/06\/14\/fda-reminds-clinicians-liraglutides-risks"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0183|cit183","unstructured":"National Institute for Health and Clinical Excellence (NICE) Hypertension - The clinical management of primary hypertension in adults; Clinical Guideline 127. 2011 Available from: http:\/\/www.nice.org.uk\/nicemedia\/live\/13561\/56007\/56007.pdf"},{"issue":"9555","key":"10.1002\/14651858.CD007654.pub4-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0140-6736(07)60033-6","article-title":"Drug treatments for obesity: orlistat, sibutramine, and rimonabant","volume":"369","author":"Padwal","year":"2007","journal-title":"The Lancet"},{"issue":"4","key":"10.1002\/14651858.CD007654.pub4-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"264-9, W64","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Annals of Internal Medicine"},{"issue":"7631","key":"10.1002\/14651858.CD007654.pub4-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1136\/bmj.39385.413113.25","article-title":"Long term pharmacotherapy for obesity and overweight: updated meta-analysis","volume":"335","author":"Rucker","year":"2007","journal-title":"BMJ"},{"issue":"1-2","key":"10.1002\/14651858.CD007654.pub4-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.mce.2008.11.018","article-title":"Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue","volume":"297","author":"Russell-Jones","year":"2009","journal-title":"Molecular and Cellular Endocrinology"},{"issue":"9548","key":"10.1002\/14651858.CD007654.pub4-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/S0140-6736(06)69571-8","article-title":"Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study","volume":"368","author":"Scheen","year":"2006","journal-title":"The Lancet"},{"issue":"10","key":"10.1002\/14651858.CD007654.pub4-BIB0189|cit189","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006423.pub2","article-title":"Glucagon-like peptide analogues for type 2 diabetes mellitus","author":"Shyangdan","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2147\/DMSO.S36276","article-title":"Lorcaserin for weight management","volume":"6","author":"Taylor","year":"2013","journal-title":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0191|cit191","unstructured":"World Health Organization. Khatib OMN El-Guindy MS (editors) Clinical guidelines for the management of hypertension. WHO EMRO Technical Publication Series 29. 2005 Available from: http:\/\/www.emro.who.int\/dsaf\/dsa234.pdf"},{"key":"10.1002\/14651858.CD007654.pub4-BIB0192|cit192","unstructured":"World Health Organization World Health Day 2013 - A global brief on hypertension. 2013 Available from: http:\/\/www.who.int\/iris\/bitstream\/10665\/79059\/1\/WHO_DCO_WHD_2013.2_eng.pdf"},{"issue":"1","key":"10.1002\/14651858.CD007654.pub4-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jama.2013.281361","article-title":"Long-term drug treatment for obesity: a systematic and clinical review","volume":"311","author":"Yanovski","year":"2014","journal-title":"JAMA"},{"issue":"3","key":"10.1002\/14651858.CD007654.pub4-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/1753-0407.12198","article-title":"Weight loss effect of glucagon-like peptide-1 mimetics on obese\/overweight adults without diabetes: A systematic review and meta-analysis of randomized controlled trials","volume":"7","author":"Zhang","year":"2015","journal-title":"Journal of Diabetes"},{"issue":"3","key":"10.1002\/14651858.CD007654.pub4-BIB0195|cit195","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007654.pub2","article-title":"Long-term effects of weight-reducing drugs in hypertensive patients","author":"Siebenhofer","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD007654.pub4-BIB0196|cit196","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007654.pub3","article-title":"Long-term effects of weight-reducing drugs in hypertensive patients","author":"Siebenhofer","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd007654.pub5","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,1,17]],"date-time":"2021-01-17T00:00:00Z","timestamp":1610841600000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD007654.pub4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T20:16:19Z","timestamp":1718396179000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD007654.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Hypertension Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,3,2]]},"references-count":196,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007654.pub4","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD007654.pub5","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,2]]}}}